pulmonari
problem
constitut
major
caus
mortal
morbid
among
patient
current
flexibl
bronchoscopi
fb
includ
routin
diagnost
tool
immunosuppress
patient
respiratori
find
clinic
radiolog
special
group
individu
immunodefici
consist
receiv
bone
marrow
transplant
bmt
diseas
malign
hematolog
diseas
primari
immun
defici
hereditari
disord
pulmonari
infiltr
develop
patient
receiv
chemotherapi
malign
significantli
affect
lack
earli
diagnosi
treatment
aetiolog
caus
pulmonari
problem
patient
advers
affect
interpret
pulmonari
radiolog
find
immunosuppress
patient
also
quit
difficult
appear
pulmonari
infiltr
also
occur
noninfecti
caus
develop
graft
versu
host
diseas
gvhd
follow
bmt
diseas
recurr
secondari
malign
infiltr
toxic
chemotherapi
addit
impair
inflammatori
respons
well
predomin
atyp
andor
nonspecif
aetiolog
caus
accur
aetiolog
determin
empir
antibiot
treatment
usual
initi
soon
possibl
patient
high
morbid
mortal
rate
delay
treatment
advers
affect
immunocompromis
patient
mani
empir
treatment
studi
report
fb
bronchoalveolar
lavag
bal
yield
diagnost
valuabl
also
report
microorgan
found
diagnos
made
fb
bal
children
adult
patient
use
fb
bal
provid
definit
diagnosi
result
appropri
treatment
initi
purpos
studi
demonstr
valu
fb
bal
determin
caus
lung
infect
develop
immunocompromis
children
investig
differ
caus
radiolog
featur
lung
infect
follow
bmt
comparison
immunosuppress
condit
evalu
reliabl
radiolog
find
predict
caus
pathogen
studi
retrospect
evalu
chart
immunosuppress
children
whose
data
retriev
patient
underw
fb
bal
januari
may
patient
demograph
featur
diagnos
bronchoscopi
indic
entri
rout
bronchoscop
complic
procedur
record
addit
preoper
pulmonari
radiolog
find
direct
radiographi
andor
hrct
macroscop
find
procedur
result
microscop
studi
bal
evalu
diagnost
yield
fb
impact
manag
evalu
patient
experienc
sever
respiratori
distress
andor
thrombocytopenia
appli
fb
appropri
time
procedur
patient
take
antibiot
andor
antifung
therapi
patient
take
multipl
antibacteri
agent
patient
take
antifung
patient
take
antivir
procedur
conduct
flexibl
bronchoscop
includ
mm
mm
mm
mm
extern
diamet
option
intub
cannula
use
entri
patient
alreadi
connect
mechan
ventil
remain
patient
either
laryng
mask
n
nasal
caviti
rout
utilis
bal
perform
focal
area
radiolog
patholog
present
right
lung
middl
lobe
widespread
involv
present
studi
approv
institut
review
board
hacettep
univers
faculti
medicin
evalu
patient
radiolog
find
chest
hrct
prior
bronchoscopi
categoris
atelectasi
consolid
appear
interstiti
infiltr
nodular
infiltr
bronchiectasi
increas
aerationair
trap
mosaic
pattern
chronic
chang
lymphadenopathi
mass
airway
anomali
major
patient
exhibit
one
find
patient
find
determin
patient
perform
cytolog
evalu
microbiolog
studi
bal
fluid
microbiolog
bal
fluid
evalu
aerob
bacteria
fungu
tuberculosi
tb
furthermor
utilis
pcr
evalu
presenc
respiratori
virus
bocaviru
coronaviru
enteroviru
human
rhinoviru
influenza
influenza
b
parainfluenza
parainfluenza
parainfluenza
parainfluenza
rsv
rsv
b
metapneumoviru
coronaviru
observ
pulmonari
infect
cmv
defin
viral
load
copi
bal
immunofluoresc
stain
method
utilis
indirect
fluoresc
antibodi
ifa
detect
pjp
perform
statist
analys
ibm
spss
window
version
softwar
packag
descript
statist
calcul
use
data
obtain
analys
percentag
frequenc
mean
standard
deviat
addit
carri
test
compar
quantit
variabl
pearson
fisher
exact
test
signific
level
p
accept
review
hospit
record
chart
immunosuppress
patient
femal
male
evalu
fb
bal
age
rang
month
year
mean
median
patient
divid
two
group
group
n
includ
patient
exhibit
primari
secondari
immunodefici
group
ii
n
includ
patient
immunosuppress
bmt
provid
detail
diagnos
characterist
patient
group
ii
present
tabl
patient
group
radiolog
evalu
prior
fb
consolid
patient
atelectasi
patient
diffuseloc
nodular
infiltr
patient
interstiti
infiltr
patient
appear
patient
bronchiectasi
patient
detect
normal
find
present
remain
patient
patient
one
radiolog
find
patient
one
find
patient
two
patient
three
detail
radiolog
result
given
supplementari
tabl
macroscop
evalu
fb
provid
find
consist
infect
patient
tracheomalacia
observ
patient
bronchomalacia
patient
airway
anomali
patient
mucos
hyperemia
hemorrhag
patient
normal
find
present
patientsin
microscop
evalu
bal
microbiolog
agent
detect
patient
tabl
among
patient
exhibit
multipl
agent
detail
microbiolog
result
given
supplementari
tabl
common
agent
streptococcu
pneumonia
n
independ
well
along
agentspati
group
ii
radiolog
evalu
group
ii
reveal
consolid
patient
atelectasi
patient
diffuseloc
nodular
infiltr
patient
diffus
interstiti
infiltr
patient
appear
patient
bronchiectasi
patient
normal
find
present
remain
patient
patient
one
find
patient
two
detail
radiolog
find
given
supplementari
tabl
macroscop
fb
patient
purul
secret
patient
tracheomalacia
patient
airway
anomali
patient
hemorrhag
patient
present
macroscop
normalth
bal
result
reveal
microbiolog
agent
patient
among
patient
multipl
agent
although
statist
signific
differ
determin
microbiolog
agent
group
viral
agent
common
microbiolog
agent
detect
bal
provid
tabl
microbiolog
radiolog
find
patient
group
group
ii
tabl
bacteri
pathogen
preval
group
group
ii
p
result
reveal
differ
two
group
regard
presenc
fungi
tb
virus
pjpaddit
differ
detect
group
base
radiolog
find
atelectasi
consolid
nodular
infiltr
interstiti
infiltr
ground
glass
bronchiectasi
one
aim
determin
role
radiolog
find
predict
caus
pathogen
group
patient
consid
togeth
signific
associ
determin
presenc
viral
pathogen
includ
cmv
radiolog
find
interstiti
infiltr
andor
appear
p
howev
signific
associ
exist
radiolog
find
presenc
bacteri
fungal
pathogen
bal
sampl
patient
abl
test
viral
agent
pcr
method
found
posit
viral
agent
patient
interstiti
infiltr
appear
likewis
patient
neg
result
viral
pcr
studi
interstiti
infiltr
andor
appear
predict
valu
aetiolog
agent
base
radiolog
find
provid
tabl
evalu
diagnost
method
relat
fb
macroscop
patholog
find
demonstr
microbi
agent
bal
reveal
diagnost
find
patient
antimicrobi
treatment
chang
patient
escal
base
identifi
pathogen
agent
patient
ganciclovir
given
patient
pulmonari
cmv
infect
treatment
start
patient
new
antibacteri
ad
patientsa
new
antifung
ad
patient
howev
empir
antibacteri
treatment
narrow
patient
pathogen
agent
clearli
identifi
compet
treatment
alreadi
use
treatment
chang
bal
microbiolog
result
provid
tabl
complic
fb
procedur
present
patient
includ
mild
temporari
hypoxia
patient
hemorrhag
patient
temporari
bradycardia
patient
resolv
procedur
discontinu
reoccur
complic
fb
procedur
result
perman
morbid
andor
mortal
result
reveal
even
though
patient
receiv
antibiot
andor
antifung
therapi
throughout
procedur
fb
bal
examin
provid
signific
data
patient
compel
enough
warrant
chang
treatment
last
year
three
retrospect
studi
conduct
similar
patient
group
studi
publish
result
patient
bmt
undergon
fb
immunodefici
lung
find
two
studi
publish
report
fb
bal
result
adult
patient
diagnos
immunodefici
studi
treatment
chang
occur
patient
whose
bal
sampl
posit
microbiolog
studi
respect
likewis
treatment
chang
also
report
respect
patient
whose
bal
sampl
neg
pathogen
agent
studi
among
patient
whose
treatment
chang
patient
treatment
increas
wherea
patient
treatment
modifi
narrow
current
treatment
tabl
overwhelm
major
patient
group
rate
therapi
escal
n
promin
especi
addit
antibiot
vs
patient
bacteri
pathogen
preval
group
group
ii
p
bacteri
divers
high
bal
result
antimicrobi
agent
time
fb
cover
pathogen
recent
report
investig
treatment
chang
also
show
higher
escal
compar
continu
treatment
nontarget
agent
follow
neg
bal
although
differ
high
rate
found
explain
slight
discrep
immunosuppress
popul
observ
posit
bal
result
ad
therapi
seem
reason
cessat
antimicrobi
agent
difficult
critic
popul
addit
includ
patient
chang
prophylaxi
treatment
dose
antibiot
lengthen
durat
current
treatment
treatment
chang
would
count
addit
effect
escal
rate
addit
find
point
overus
antibiot
tendenc
continu
use
even
case
without
object
evid
support
use
result
also
provid
evid
bal
evalu
prove
valuabl
approach
detect
varieti
aetiolog
agent
cmv
tb
resist
microorgan
research
also
investig
whether
differ
aetiolog
agent
radiolog
featur
accord
pulmonari
infect
develop
follow
bmt
well
immunodefici
state
determin
bmt
group
fewer
bacteri
agent
group
immunodefici
differ
appear
aetiolog
agent
result
may
relat
protect
effect
prophylact
antibiot
administ
sinc
begin
bmt
process
well
prepar
regimen
caus
deplet
order
prevent
occurr
graft
versu
host
diseas
may
play
critic
role
increas
frequenc
presenc
viral
opportunist
agent
bmt
patient
result
also
reveal
bacteri
agent
particular
pneumonia
recognis
common
caus
pneumonia
patient
immunodefici
bmt
also
extrem
import
agent
review
anoth
aim
investig
evalu
sensit
hrct
predict
caus
pathogen
fb
bal
conduct
gener
practic
bacteri
viral
fungal
infect
suspect
respect
caus
agent
presenc
consolid
atelectasi
infiltr
appear
nodular
appear
empir
treatment
determin
initi
accordingli
studi
demonstr
interstiti
infiltr
appear
ct
significantli
relat
cmv
viral
agent
bal
success
show
bacteria
fungi
detect
bal
low
importantli
lack
expect
pathogen
immun
dysregul
may
also
reason
find
studi
recent
year
role
radiolog
find
detect
infecti
agent
specifi
opac
nodul
appear
associ
pathogen
addit
rizik
et
evalu
children
immunodefici
determin
although
bal
result
led
treatment
chang
case
type
radiolog
find
focal
lobar
vs
diffus
age
vs
ultim
associ
treatment
chang
therefor
studi
appear
first
evalu
reliabl
radiolog
find
predict
aetiolog
agent
children
immunodefici
well
associ
viral
aetiolog
radiolog
find
accord
data
studi
recommend
viral
investig
initi
earli
period
treatment
well
start
earli
antivir
treatment
patient
present
appear
hrct
addit
recommend
find
continu
investig
studi
larger
patient
group
cohort
limit
current
studi
includ
retrospect
natur
well
use
prophylact
antibiot
antivir
patient
prior
studi
howev
previou
research
past
recent
similar
investig
also
conduct
empir
treatment
fact
could
evalu
number
unit
grew
bal
anoth
major
limit
studi
contamin
oropharyng
flora
rule
especi
patient
one
isol
pathogen
howev
consid
result
manag
therapi
seriou
complic
bronchoscopi
detect
juvenil
age
group
among
immunocompromis
patient
found
studi
report
previou
literatur
howev
case
adult
patient
immun
defici
exhibit
higher
incid
seriou
conclus
fb
bal
done
patient
soon
possibl
order
clarifi
caus
agent
way
appropri
treatment
administ
side
effect
high
cost
may
attribut
unnecessari
treatment
regimen
may
mitig
financi
conflict
interest
disclos
n
g
design
studi
perform
studi
contribut
import
reagent
collect
data
analys
data
wrote
paper
e
yalcin
design
studi
perform
studi
contribut
import
reagent
wrote
paper
b
oguz
acquisit
data
interpret
contribut
import
reagent
ocal
contribut
import
reagent
b
kuskonmaz
contribut
import
reagent
n
emiralioglu
perform
studi
contribut
import
reagent
dogru
ersoz
design
studi
perform
studi
contribut
import
reagent
u
ozcelik
design
studi
perform
studi
contribut
import
reagent
tezcan
contribut
import
reagent
n
kiper
design
studi
perform
studi
contribut
import
reagent
appropri
ethic
committe
approv
obtain
hacettep
univers
research
report
